Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Cost of Revenue (2020 - 2025)

Bioventus (BVS) has disclosed Cost of Revenue for 6 consecutive years, with $49.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 3.66% year-over-year to $49.1 million, compared with a TTM value of $179.9 million through Dec 2025, down 2.77%, and an annual FY2025 reading of $179.9 million, down 2.77% over the prior year.
  • Cost of Revenue was $49.1 million for Q4 2025 at Bioventus, up from $44.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $51.6 million in Q4 2022 and bottomed at $22.2 million in Q2 2021.
  • Average Cost of Revenue over 5 years is $42.9 million, with a median of $44.3 million recorded in 2022.
  • The sharpest move saw Cost of Revenue skyrocketed 89.63% in 2021, then dropped 9.0% in 2024.
  • Year by year, Cost of Revenue stood at $42.6 million in 2021, then rose by 21.1% to $51.6 million in 2022, then decreased by 4.89% to $49.1 million in 2023, then grew by 3.79% to $51.0 million in 2024, then fell by 3.66% to $49.1 million in 2025.
  • Business Quant data shows Cost of Revenue for BVS at $49.1 million in Q4 2025, $44.4 million in Q3 2025, and $45.6 million in Q2 2025.